อ้างอิง ของ BBV152

  1. ↑ Corum, Jonathan; Zimmer, Carl (2021-04-26). "How Bharat Biotech's Vaccine Works". The New York Times. ISSN 0362-4331. สืบค้นเมื่อ 2021-04-29.
  2. ↑ "ICMR teams up with Bharat Biotech to develop Covid-19 vaccine". Livemint (ภาษาอังกฤษ). 9 May 2020.
  3. ↑ Chakrabarti A (10 May 2020). "India to develop 'fully indigenous' Covid vaccine as ICMR partners with Bharat Biotech". ThePrint.
  4. ↑ "India's First COVID-19 Vaccine Candidate Approved for Human Trials". The New York Times. 29 June 2020.
  5. ↑ "Human clinical trials of potential Covid-19 vaccine 'COVAXIN' started at AIIMS". DD News. Prasar Bharati, Ministry of I & B, Government of India. 25 July 2020.
  6. ↑ Press, Associated (25 July 2020). "Asia Today: Amid new surge, India tests potential vaccine". Washington Post. สืบค้นเมื่อ 17 December 2020.
  7. ↑ "Delhi: 30-year-old is first to get dose of trial drug Covaxin". The Indian Express (ภาษาอังกฤษ). 25 July 2020.
  8. ↑ Perappadan, Bindu Shajan (16 December 2020). "Coronavirus | Covaxin phase-1 trial results show promising results". The Hindu (ภาษาอังกฤษ). สืบค้นเมื่อ 17 December 2020.
  9. ↑ Sabarwal, Harshit (16 December 2020). "Covaxin's phase 1 trial result shows robust immune response, mild adverse events". Hindustan Times (ภาษาอังกฤษ). สืบค้นเมื่อ 17 December 2020.
  10. ↑ Ella, Raches; Vadrevu, Krishna Mohan; Jogdand, Harsh; Prasad, Sai; Reddy, Siddharth; Sarangi, Vamshi; Ganneru, Brunda; Sapkal, Gajanan; Yadav, Pragya; Abraham, Priya; Panda, Samiran; Gupta, Nivedita; Reddy, Prabhakar; Verma, Savita; Rai, Sanjay Kumar; Singh, Chandramani; Redkar, Sagar Vivek; Gillurkar, Chandra Sekhar; Kushwaha, Jitendra Singh; Mohapatra, Satyajit; Rao, Venkat; Guleria, Randeep; Ella, Krishna; Bhargava, Balram (21 January 2021). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial". The Lancet Infectious Diseases (ภาษาEnglish). doi:10.1016/S1473-3099(20)30942-7.CS1 maint: unrecognized language (link) PMID 33485468. PMC 7825810.
  11. 1 2 Ella, Raches; Reddy, Siddhart; Jogdand, Harsh; Sarangi, Vamsi; Ganneru, Brunda; Prasad, Sai; Das, Dipankar; Dugyala, Raju; Praturi, Usha; Sakpal, Gajanan; Yadav, Pragya; Reddy, Prabhakar; Verma, Savita; Singh, Chandramani; Redkar, Sagar Vivek; Singh, Chandramani; Gillurkar, Chandra Sekhar; Kushwaha, Jitendra Singh; Mohapatra, Satyajit; Mohapatra, Satyajit; Bhate, Amit; Rai, Sanjay; Panda, Samiran; Abraham, Priya; Gupta, Nivedita; Ella, Krishna; Bhargav, Balram; Vadrevu, Krishna Mohan (8 March 2021). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial". The Lancet Infectious Diseases (ภาษาEnglish). doi:10.1016/S1473-3099(21)00070-0.CS1 maint: unrecognized language (link) PMID 33705727.
  12. ↑ "Coronavirus | Covaxin Phase III trial from November". The Hindu (ภาษาอังกฤษ). 23 October 2020.
  13. ↑ Ganneru, Brunda; Jogdand, Harsh; Daram, Vijaya Kumar; Das, Dipankar; Molugu, Narasimha Reddy; Prasad, Sai D.; Kannappa, Srinivas V.; Ella, Krishna M.; Ravikrishnan, Rajaram; Awasthi, Amit; Jose, Jomy; Rao, Panduranga; Kumar, Deepak; Ella, Raches; Abraham, Priya; Yadav, Pragya D.; Sapkal, Gajanan N.; Shete-Aich, Anita; Desphande, Gururaj; Mohandas, Sreelekshmy; Basu, Atanu; Gupta, Nivedita; Vadrevu, Krishna Mohan (23 April 2021). "Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation". iScience (ภาษาEnglish). 24 (4). doi:10.1016/j.isci.2021.102298. ISSN 2589-0042.CS1 maint: unrecognized language (link) PMID 33723528. PMC 7944858.
  14. ↑ "An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers". clinicaltrials.gov (Registry). United States National Library of Medicine. NCT04641481. สืบค้นเมื่อ 2020-11-26.
  15. ↑ "Bharat Biotech begins Covaxin Phase III trials". The Indian Express (ภาษาอังกฤษ). 18 November 2020.
  16. ↑ Sen M (2 December 2020). "List of states that have started phase 3 trials of India's first Covid vaccine". mint (ภาษาอังกฤษ).
  17. ↑ "70%-80% Drop In Participation For Phase 3 Trials Of Covaxin: Official". NDTV. 17 December 2020.
  18. ↑ "Bharat Biotech's Covaxin given conditional nod based on incomplete Phase 3 trial results data". The Print. 3 January 2021.
  19. ↑ Kumar, N. Ravi (3 March 2021). "Bharat Biotech says COVID-19 vaccine Covaxin shows 81% efficacy in Phase 3 clinical trials". The Hindu (ภาษาอังกฤษ).
  20. ↑ "Inside the B.1.1.7 Coronavirus Variant". The New York Times. 18 January 2021. สืบค้นเมื่อ 29 January 2021.
  21. ↑ Sapkal, Gajanan N; Yadav, Pragya D; Ella, Raches; Deshpande, Gururaj R; Sahay, Rima R; Gupta, Nivedita; Mohan, V Krishna; Abraham, Priya; Panda, Samiran; Bhargava, Balram (27 March 2021). "Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B 1.1.7 variant of SARS-CoV-2". Journal of Travel Medicine. doi:10.1093/jtm/taab051. ISSN 1708-8305. PMID 33772577.
  22. ↑ Mascarenhas, Anuradha (21 April 2021). "Covaxin neutralises double mutant strain of SARS-CoV-2: ICMR study". The Indian Express (ภาษาอังกฤษ).
  23. ↑ Yadav, Pragya D.; Sapkal, Gajanan N.; Abraham, Priya; Ella, Raches; Deshpande, Gururaj; Patil, Deepak Y.; Nyayanit, Dimpal A.; Gupta, Nivedita; Sahay, Rima R.; Shete, Anita M.; Panda, Samiran; Bhargava, Balram; Mohan, V. Krishna (23 April 2021). "Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees". bioRxiv: 2021.04.23.441101. doi:10.1101/2021.04.23.441101.
  24. ↑ Hoeksema F, Karpilow J, Luitjens A, Lagerwerf F, Havenga M, Groothuizen M, และคณะ (April 2018). "Enhancing viral vaccine production using engineered knockout vero cell lines - A second look". Vaccine. 36 (16): 2093–2103. doi:10.1016/j.vaccine.2018.03.010. PMC 5890396. PMID 29555218.
  25. ↑ "Coronavirus vaccine update: Bharat Biotech's Covaxin launch likely in Q2 of 2021, no word on pricing yet". www.businesstoday.in. India Today Group. สืบค้นเมื่อ 13 December 2020.
  26. ↑ "Odisha fast tracks coronavirus vaccine manufacturing unit". The New Indian Express. 7 November 2020.
  27. ↑ Raghavan P (24 September 2020). "Bharat Biotech exploring global tie-ups for Covaxin manufacturing". The Indian Express (ภาษาอังกฤษ).
  28. ↑ Reuters Staff (2020-12-22). "Ocugen to co-develop Bharat Biotech's COVID-19 vaccine candidate for U.S." Reuters (ภาษาอังกฤษ). สืบค้นเมื่อ 2021-01-05.
  29. ↑ "Bharat Biotech, Ocugen to co-develop Covaxin for US market". The Economic Times. สืบค้นเมื่อ 2021-01-05.
  30. ↑ "Bharat Biotech inks pact with Precisa Med to supply Covaxin to Brazil". mint (ภาษาอังกฤษ). 12 January 2021.
  31. ↑ Deshpande, Alok (15 April 2021). "Haffkine Institute gets Centre's nod to produce Covaxin". The Hindu (ภาษาอังกฤษ). สืบค้นเมื่อ 15 April 2021.
  32. ↑ Vora, Rutam (20 April 2021). "IIL confident of Covaxin rollout by August". @businessline (ภาษาอังกฤษ). The Hindu.
  33. ↑ Ghosh N (7 December 2020). "Bharat Biotech seeks emergency use authorization for Covid-19 vaccine". Hindustan Times (ภาษาอังกฤษ).
  34. ↑ "Coronavirus | After SII, Bharat Biotech seeks DCGI approval for Covaxin". The Hindu (ภาษาอังกฤษ). 7 December 2020.
  35. ↑ "Expert panel recommends granting approval for restricted emergency use of Bharat Biotech's Covaxin". The Indian Express (ภาษาอังกฤษ). 2 January 2021.
  36. ↑ "Coronavirus: India approves vaccines from Bharat Biotech and Oxford/AstraZeneca". BBC News (ภาษาอังกฤษ). 2021-01-03. สืบค้นเมื่อ 2021-01-03.
  37. ↑ "Disputes Mount, but Heedless Govt Intent on Rolling Vaccine Candidates Out". The Wire. 12 January 2021.
  38. ↑ "AIPSN urges govt to reconsider emergency approval for Covaxin till Phase 3 data is published - Health News , Firstpost". Firstpost. 8 January 2021.
  39. ↑ Manral, Karan (4 March 2021). "Zimbabwe approves Covaxin, first in Africa to okay India-made Covid-19 vaccine". Hindustan Times. สืบค้นเมื่อ 6 March 2021.
  40. ↑ "Iran issues permit for emergency use for three other COVID-19 vaccines: Official". IRNA English (ภาษาอังกฤษ). 17 February 2021.
  41. ↑ "Dr Jagutpal: Une cargaison de 200 000 vaccins Covaxin débarque demain". L'Express. 19 March 2021.
  42. ↑ Sharma, Gopal (2021-03-19). "Nepal becomes third country to give emergency nod to Indian vaccine COVAXIN". Reuters (ภาษาอังกฤษ). สืบค้นเมื่อ 2021-03-19.
  43. ↑ "India provides 100,000 doses of Covaxin to Paraguay". 30 March 2021.
  44. ↑ Staff, Reuters (2021-04-07). "Mexico authorizes emergency use of Indian COVID-19 vaccine". Reuters (ภาษาอังกฤษ). สืบค้นเมื่อ 2021-04-07.
  45. ↑ "Covaxin, Janssen approved for emergency use in PH". CNN Philippines. 19 April 2021.
  46. ↑ Bharadwaj, Swati (20 April 2021). "Covid-19: Bharat Biotech ramps up Covaxin capacity to 700 million doses per annum". Times of India.
  47. ↑ Som, Vishnu (March 31, 2021). "Brazil Says "No" To Covaxin, Bharat Biotech Explains". NDTV. สืบค้นเมื่อ April 18, 2021.